Secondary antifungal prophylaxis in hematopoietic stem cell transplantation (HSCT)/acute leukemia patients

Current Infectious Disease Reports

Volumn 13, Issue 6, 2011, Pages 528-535

  El Cheikh, Jean ^a  

^a INSTITUT PAOLI CALMETTES   (France)

Author keywords

Allogeneic HSCT; Antifungal agents; Invasive fungal infection; Secondary prophylaxis

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; BUSULFAN; CASPOFUNGIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUCONAZOLE; IMMUNOSUPPRESSIVE AGENT; ITRACONAZOLE; PLACEBO; POSACONAZOLE; PREDNISONE; STEROID; TRIAZOLE; VORICONAZOLE;

ACUTE LEUKEMIA; APLASIA; APPLICATION SITE REACTION; CANCER PATIENT; CANDIDIASIS; DISEASE DURATION; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG EFFICACY; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG TISSUE LEVEL; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; IMMUNE DEFICIENCY; INFECTION PREVENTION; INFECTION RISK; LIVER TOXICITY; LUNG ASPERGILLOSIS; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NONHUMAN; OVERALL SURVIVAL; RELAPSE; REVIEW; SECONDARY PREVENTION; SYSTEMIC MYCOSIS;

EID: 81155135220     PISSN: 15233847     EISSN: 15343146     Source Type: Journal    
DOI: 10.1007/s11908-011-0214-8     Document Type: Review

References (47)

1. M Mohty JO Bay C Faucher, et al. 2003 Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen Blood 102 470 476 12649133 10.1182/blood-2002-12-3629 1:CAS:528:DC%2BD3sXlslGitro%3D (Pubitemid 36841962)
2. DP Kontoyiannis KA Marr BJ Park, et al. 2010 Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database Clin Infect Dis 50 8 1091 1100 20218877 10.1086/651263 These authors provide an excellent review of this topic from a prospective study
3. E Jantunen P Ruutu L Niskanen, et al. 1997 Incidence and risk factors for invasive fungal infections in allogeneic BMT recipients Bone Marrow Transplant 19 801 808 9134172 10.1038/sj.bmt.1700737 1:STN:280:DyaK2s3nvFOqug%3D%3D (Pubitemid 27207896)
4. R Martino M Subirá M Rovira, et al. 2002 Invasive fungal infections after allogeneic peripheral blood stem cell transplantation: incidence and risk factors in 395 patients Br J Haematol 116 475 482 11841455 10.1046/j.1365-2141.2002.03259.x (Pubitemid 34155525)
5. M Mohty W Jacot C Faucher, et al. 2003 Infectious complications following allogeneic HLA-identical sibling transplantation with antithymocyte globulin-based reduced intensity preparative regimen Leukemia 17 2168 2177 12931226 10.1038/sj.leu.2403105 1:CAS:528:DC%2BD3sXotlartb4%3D (Pubitemid 37428382)
6. T Fukuda M Boeckh RA Carter, et al. 2003 Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after non myeloablative conditioning Blood 102 827 833 12689933 10.1182/blood-2003-02-0456 1:CAS:528:DC%2BD3sXlvFCmsLs%3D (Pubitemid 36917771)
7. A Nosari M Ravini R Cairoli, et al. 2007 Surgical resection of persistent pulmonary fungus nodules and secondary prophylaxis are effective in preventing fungal relapse in patients receiving chemotherapy or bone marrow transplantation for leukemia Bone Marrow Transplant 39 10 631 635 17384656 10.1038/sj.bmt. 1705655 1:CAS:528:DC%2BD2sXkslyiu7o%3D Epub 2007 Mar 26 (Pubitemid 46722843)
8. • Maertens J, Marchetti O, Herbrecht R, et al.: European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3-2009 Update. Bone Marrow Transplant. 2010 Jul 26. The goal of this paper is to summarize the new proposals guidelines from ECIL 3, based on the results of studies published after the ECIL 2 meeting.
9. J El-Cheikh L Castagna L Wang, et al. 2010 Impact of prior invasive aspergillosis on outcome in patients receiving reduced-intensity conditioning allogeneic hematopoietic stem cell transplant Leuk Lymphoma 51 9 1705 1710 20629522 10.3109/10428194.2010.500433 1:CAS:528:DC%2BC3cXhtV2qsbvI This study demonstrates that Allo-HSCT with RIC could be performed in this high risk population with previous aspergillosis
10. K Allinson H Kolve HG Gumbinger, et al. 2008 Secondary antifungal prophylaxis in paediatric allogeneic haematopoietic stem cell recipients J Antimicrob Chemother 61 3 734 742 18238891 10.1093/jac/dkm521 1:CAS:528:DC%2BD1cXisVKnsLs%3D Epub 2008 Jan 31. This prospective pediatric series supports the notion that secondary antifungal prophylaxis for possible or probable IPA can be safely achieved in allogeneic HSCT (Pubitemid 351321154)
11. T Fukuda M Boeckh KA Guthrie, et al. 2004 Invasive aspergillosis before allogeneic hematopoietic stem cell transplantation: 10-year experience at a single transplant center Biol Blood Marrow Transplant 10 494 503 15205670 10.1016/j.bbmt.2004.02.006 This large retrospective study demonstrates that the duration of antifungal therapy before transplantation, the resolution of radiographic abnormalities, and conditioning regimens are important variables to consider for minimizing the risk for IA recurrence and TRM after allo-HSCT (Pubitemid 38772003)
12. R Martino R Parody T Fukuda, et al. 2006 Impact of the intensity of the pre transplantation conditioning regimen in patients with prior invasive aspergillosis undergoing allogeneic hematopoietic stem cell transplantation: A retrospective survey of the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation Blood 108 9 2928 2936 16720833 10.1182/blood-2006-03-008706 1:CAS:528:DC%2BD28XhtFygtrvO This important retrospective study evaluated the variables that increased the 2-year Cumulative Incidence of IA progression were (1) longer duration of neutropenia after transplantation; (2) advanced status of the underlying disease; and (3) less than 6 weeks from start of systemic anti-Aspergillus therapy and the allo-HSCT
13. C Cordonnier M Rovira J Maertens, et al. 2010 Voriconazole for Secondary Prophylaxis of Invasive Fungal Infections in Patients with Allogeneic Stem Cell Transplants (VOSIFI) study group; Infectious Diseases Working Party, European Group for Blood and Marrow Transplantation Haematologica 95 10 1762 1768 20634495 10.3324/haematol.2009.020073 Epub 2010 Jul 15. This very important prospective, open-label, multicenter trial elucidated the role of Voriconazole for secondary prophylaxis of systemic fungal infection after allo-HSCT
14. B De Pauw TJ Walsh JP Donnelly, et al. 2008 Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group Clin Infect Dis 46 1813 1821 18462102 10.1086/588660
15. Y Masamoto Y Nannya M Kurokawa 2011 Voriconazole is effective as secondary antifungal prophylaxis in leukemia patients with prior pulmonary fungal disease: case series and review of literature J Chemother 23 1 17 23 21482489 1:CAS:528:DC%2BC3MXovVKjuro%3D This review retrieved the previous reports of myelosuppressive therapies after IFI using various secondary prophylaxes, and showed that voriconazole is the most effective drug to suppress IFI relapses
16. NV Sipsas DP Kontoyiannis 2006 Clinical issues regarding relapsing aspergillosis and the efficacy of secondary antifungal prophylaxis in patients with hematological malignancies Clin Infect Dis 42 11 1584 1591 16652316 10.1086/503844 Epub 2006 Apr 24. Review. This important review highlighted the existing knowledge regarding the pathogenesis, the risk factors, and the natural history of relapsing invasive aspergillosis and review the limited data regarding the role of ASP
17. C Cordonnier S Maury C Pautas, et al. 2004 Secondary antifungal prophylaxis with voriconazole to adhere to scheduled treatment in leukemic patients and stem cell transplant recipients Bone Marrow Transplant 33 9 943 948 15034546 10.1038/sj.bmt.1704469 1:CAS:528:DC%2BD2cXjt1Cmu7k%3D This small but homogeneous series indicates that voriconazole may be useful to prevent fungal relapse during at-risk periods in leukemic patients (Pubitemid 38660128)
18. AJ Ullmann JH Lipton DH Vesole, et al. 2007 Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease N Engl J Med. 356 4 335 347 17251530 10.1056/NEJMoa061098 1:CAS:528:DC%2BD2sXhtVGktb4%3D (Pubitemid 46148776)
19. KA Marr F Crippa W Leisenring, et al. 2004 Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants Blood 103 1527 1533 14525770 10.1182/blood-2003-08-2644 1:CAS:528:DC%2BD2cXhsVSlu7k%3D (Pubitemid 38168674)
20. WB Stam AK O'Sullivan B Rijnders, et al. 2008 Economic evaluation of posaconazole vs. standard azole prophylaxis in high risk neutropenic patients in the Netherlands Eur J Haematol 81 6 467 474 18754857 10.1111/j.1600-0609.2008. 01141.x
21. TR Rogers S Frost 2009 Newer antifungal agents for invasive fungal infections in patients with haematological malignancy Brit J Haematol 144 629 641 10.1111/j.1365-2141.2008.07412.x 1:CAS:528:DC%2BD1MXktVeltLY%3D
22. GP Bodey EJ Anaissie LS Elting, et al. 1994 Antifungal prophylaxis during remission induction therapy for acute leukemia fluconazole versus intravenous amphotericin B Cancer 73 2099 2106 8156515 10.1002/1097-0142(19940415)73: 8<2099::AID-CNCR2820730814>3.0.CO;2-N 1:STN:280:DyaK2c3gsl2luw%3D%3D (Pubitemid 24107964)
23. R Herbrecht DW Denning TF Patterson, et al. 2002 Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis N Engl J Med 347 408 415 12167683 10.1056/NEJMoa020191 1:CAS:528:DC%2BD38XlvFKrt7o%3D (Pubitemid 34851833)
24. I Bekersky GW Boswell R Hiles, et al. 2000 Safety, toxicokinetics and tissue distribution of long-term intravenous liposomal amphotericin B (AmBisome): a 91-day study in rats Pharm Res 17 1494 1502 11303959 10.1023/A:1007605024942 1:CAS:528:DC%2BD3MXit1egsLk%3D (Pubitemid 32217558)
25. JW Lee MA Amantea PA Francis, et al. 1994 Pharmacokinetics and safety of a unilamellar liposomal formulation of amphotericin B (AmBisome) in rabbits Antimicrob Agents Chemother 38 713 718 8031034 1:CAS:528:DyaK2cXivVSjurc%3D (Pubitemid 24114006)
26. GW Boswell I Bekersky D Buell, et al. 1998 Toxicological profile and pharmacokinetics of a unilamellar liposomal vesicle formulation of amphotericin B in rats Antimicrob Agents Chemother 42 263 268 9527770 1:CAS:528: DyaK1cXnsFGrtQ%3D%3D (Pubitemid 28114429)
27. TJ Walsh JL Goodman P Pappas, et al. 2001 Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study Antimicrob Agents Chemother 45 3487 3496 11709329 10.1128/AAC.45.12.3487-3496.2001 1:CAS:528:DC%2BD3MXovVOltLc%3D (Pubitemid 33107867)
28. J Tollemar K Höckerstedt BG Ericzon, et al. 1994 Fungal prophylaxis with Am Bisome in liver and bone marrow transplant recipients: results of two randomized double-blind studies Transplant Proc 26 1833 8030161 1:STN:280:DyaK2czgtlSqsw%3D%3D (Pubitemid 24211810)
29. C Cordonnier M Mohty C Faucher, et al. 2008 Safety of a weekly high dose of liposomal amphotericin B for prophylaxis of invasive fungal infection in immunocompromised patients: PROPHYSOME Study Int J Antimicrob Agents 31 135 141 18162375 10.1016/j.ijantimicag.2007.10.001 1:CAS:528:DC%2BD1cXislOnsA%3D%3D
30. JJ Vehreschild M Sieniawski S Reuter, et al. 2009 Efficacy of caspofungin and itraconazole as secondary antifungal prophylaxis: analysis of data from a multinational case registry Int J Antimicrob Agents 34 5 446 450 19700265 10.1016/j.ijantimicag.2009.06.025 1:CAS:528:DC%2BD1MXhtFagsLvN Epub 2009 Aug. This study described that Both Itraconazole and Caspofungin were equally effective in preventing second episodes of IFI
31. A Song DL Yang Y Huang, et al. 2010 Secondary antifungal prophylaxis in hematological malignancies in a tertiary medical center Int J Hematol 92 5 725 731 21125359 10.1007/s12185-010-0723-5 1:CAS:528:DC%2BC3cXhsFCqsbfK Epub 2010 Dec 3. This important retrospective study demonstrated that the use of high dose corticosteroid and duration of neutropenia ≥ 14 days were risk factors of SAP failure. Patients with the two risk factors concurrently were in high risk and needed special concern
32. KA Marr RA Carter M Boeckh, et al. 2002 Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors Blood 100 4358 4366 12393425 10.1182/blood-2002-05-1496 1:CAS:528:DC%2BD38XpsFCqs7Y%3D (Pubitemid 35429674)
33. K Hubel RA Carter WC Liles, et al. 2002 Granulocyte transfusion therapy for infections in candidates and recipients of HPC transplantation: a comparative analysis of feasibility and outcome for community donors versus related donors Transfusion. 42 1414 1421 12421213 10.1046/j.1537-2995.2002. 00249.x
34. MC Dignani EJ Anaissie JP Hester, et al. 1997 Treatment of neutropenia-related fungal infections with granulocyte colony-stimulating factor-elicited white blood cell transfusions: a pilot study Leukemia. 11 10 1621 1630 9324280 10.1038/sj.leu.2400811 1:CAS:528:DyaK2sXnsV2iu7c%3D (Pubitemid 27458598)
35. Saoulidis S, Simitsopoulou M, Dalakiouridou M, et al.: Antifungal activity of posaconazole and granulocyte colony-stimulating factor in the treatment of disseminated zygomycosis (mucormycosis) in a neutropaenic murine model. Mycoses. 2010 Oct 29. doi: 10.1111/j.1439-0507.2010.01958.x.
36. A Safdar GH Rodriguez MJ De Lima, et al. 2007 Infections in 100 cord blood transplantations: spectrum of early and late post transplant infections in adult and pediatric patients 1996-2005 Medicine (Baltimore). 86 6 324 333 10.1097/MD.0b013e31815c52b0 (Pubitemid 351326055)
37. DP Kontoyiannis 2011 Antifungal prophylaxis in hematopoietic stem cell transplant recipients: the unfinished tale of imperfect success Bone Marrow Transplantation 46 165 173 21042306 10.1038/bmt.2010.256 1:CAS:528: DC%2BC3MXhs1yrsLg%3D This paper illustrated that not all hematopoietic stem cell transplant recipients have the same risk of IFI. New prophylactic strategies using risk stratification and new broad-spectrum antifungals have the potential for reducing IFI-associated mortality in these patients
38. V Balloy M Huerre JP Latgé M Chignard 2005 Differences in patterns of infection and inflammation for corticosteroid treatment and chemotherapy in experimental invasive pulmonary aspergillosis Infect Immun. 73 1 494 503 15618189 10.1128/IAI.73.1.494-503.2005 1:CAS:528:DC%2BD2MXisFyluw%3D%3D (Pubitemid 40041144)
39. I Buggia M Zecca EP Alessandrino, et al. 1996 Itraconazole can increase systemic exposure to busulfan in patients given bone marrow transplantation. GITMO (Gruppo Italiano Trapianto di Midollo Osseo) Anticancer Res 16 4A 2083 2088 8712747 1:CAS:528:DyaK28XltFyktL0%3D (Pubitemid 26270729)
40. P De Fabritiis A Spagnoli P Di Bartolomeo, et al. 2007 Efficacy of caspofungin as secondary prophylaxis in patients undergoing allogeneic stem cell transplantation with prior pulmonary and/or systemic fungal infection Bone Marrow Transplant 40 245 249 17529996 10.1038/sj.bmt.1705720 Epub 2007 May 28 (Pubitemid 47108468)
41. DJ Winston RT Maziarz PH Chandrasekar, et al. 2003 Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial Ann Intern Med 138 705 713 12729424 1:CAS:528:DC%2BD3sXktVyhsLg%3D
42. OA Cornely J Maertens DJ Winston, et al. 2007 Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia N Engl J Med 356 348 359 17251531 10.1056/NEJMoa061094 1:CAS:528:DC%2BD2sXhtVGrsrw%3D (Pubitemid 46148777)
43. WH Krüger B Rüssmann M de Wit, et al. 2005 Haemopoietic cell transplantation of patients with a history of deep or invasive fungal infection during prophylaxis with liposomal amphotericin B Acta Haematol. 113 2 104 108 15802888 10.1159/000083447 (Pubitemid 40522813)
44. J El-Cheikh C Faucher S Furst, et al. 2007 High-dose weekly liposomal amphotericin B antifungal prophylaxis following reduced-intensity conditioning allogeneic stem cell transplantation Bone Marrow Transplant 39 301 306 17262059 10.1038/sj.bmt.1705592 1:CAS:528:DC%2BD2sXhvFWkt7c%3D (Pubitemid 46322637)
45. J El Cheikh L Castagna L Wang, et al. 2010 Once-weekly liposomal amphotericin B for prophylaxis of invasive fungal infection after graft-versus-host disease in allogeneic hematopoietic stem cell transplantation: a comparative retrospective single-center study Hematol Oncol Stem Cell Ther 3 4 167 173 21150235
46. •• Rogers TR, Slavin MA, Donnelly JP∈: Antifungal prophylaxis during treatment for haematological malignancies: are we there yet? Br J Haematol. 2011 Apr 20. doi: 10.1111/j.1365-2141.2011.08650.x. These authors provide an excellent review of this topic.
47. P Zhang A Song Z Wang, et al. 2009 Hematopoietic SCT in patients with a history of invasive fungal infection Bone Marrow Transplant 43 7 533 537 19104496 10.1038/bmt.2008.356 1:STN:280:DC%2BD1M3mt12isA%3D%3D Epub 2008 Dec 22